Meeting
2022 ASCO Annual Meeting
Subcutaneous nivolumab versus intravenous nivolumab in patients with previously treated, advanced, or metastatic clear cell renal cell carcinoma.
Authors
Matias Rodrigo Chacon
Instituto Medico Especializado Alexander Fleming, Buenos Aires, Argentina
Matias Rodrigo Chacon , Hernan J. Cutuli , Sergio Bracarda , Marco Maruzzo , Maria Teresa Bourlon , Carmel Jacobs , Begoña Pérez-Valderrama , Ignacio Magri , Martin Richardet , Piotr Centkowski , Simon Yuen Fai Fu , Pablo Gurman , Srivani Konduri , Zhuoxin Yu , Heather Vezina , Saby George , Laurence Albiges
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Other GU Kidney and Bladder Cancer
Clinical Trial Registration Number
NCT04810078
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4621)
DOI
10.1200/JCO.2022.40.16_suppl.TPS4621
Abstract #
TPS4621
Poster Bd #
100b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer.
First Author: Daisuke Kotani
Poster
2023 ASCO Annual Meeting
ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.
First Author: Richard F. Riedel
Poster
2023 ASCO Annual Meeting
Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.
First Author: Thierry Landre
Poster
2023 ASCO Genitourinary Cancers Symposium
Overall survival, efficacy, and safety outcomes beyond front-line modern therapies in metastatic clear-cell renal cell carcinoma.
First Author: Jordyn Kreutzfeldt